

*Innovative medical devices for the treatment of diabetes*

## Defymed strengthens its position as a worldwide leader

Strasbourg, France, February 2018 - French-based Medtech company Defymed confirms its global position. Recognized by its peers for the development of two innovative medical devices - ExOlin<sup>®</sup>, an insulin delivery device, and MailPan<sup>®</sup>, a bioartificial pancreas – the company intends to strengthen its position as a worldwide leader in innovative physiological treatments of diabetes and chronic diseases.

To support the entry of ExOlin<sup>®</sup> into the clinical phase and the scientific development of MailPan<sup>®</sup>, Defymed is seeking 10 million euros in 2018, backed by specialist health and Medtech funds. In the spirit of open innovation, Defymed also intends to draw on new partnerships in Asia, Europe, and the USA.

### Diabetes, scourge of the 21<sup>st</sup> century

Diabetes is a condition characterized by an abnormally elevated level of sugar in the blood. Considered to be one of the **major epidemics of the 21<sup>st</sup> century**, diabetes risks affecting up to **600 million people worldwide in the next 15 years**. Current insulin delivery systems available on the market do not meet all medical needs. In addition, only 23.5% of diabetic men and 36.4% of diabetic women correctly control their blood sugar levels.



### Future technologies at patients' disposal

Putting the patient at the heart of innovation and improving their quality of life, is what drives Defymed. As part of this approach, two innovative medical devices, ExOlin<sup>®</sup> and MailPan<sup>®</sup>, have been developed by Defymed to provide patients with a more physiological treatment.



Through its more **physiological approach** for insulin delivery, ExOlin<sup>®</sup> shall allow diabetics to achieve **more stable blood sugar levels** and consequently, a **better quality of life**. This device will enter the clinical phase in 2018, and in the future, may be adapted to other applications and pathologies requiring a physiological delivery of drugs or active ingredients.

The second device, MailPan<sup>®</sup>, is a breakthrough solution designed to considerably improve the daily lives of patients suffering from Type 1 diabetes through an **automated and physiological treatment**. This bioartificial pancreas should reestablish normal insulin production in response to fluctuations in blood sugar levels. This device offers a **real alternative to pancreas transplants**, whilst also **avoiding the need for antirejection treatments**.

---

**DEFYMED**

8 avenue Dante  
67200 Strasbourg, France  
Tel. +33 (0)39-041-0446

[www.defymed.com](http://www.defymed.com)

## A roadmap from now to 2020

Armed with its well established quality management system (ISO 13485:2016), Defymed has already acquired 2 exclusive licenses and filed 5 proprietary international patents.

Defymed's primary objectives include increasing its international outlook by developing new partnerships in Asia, Europe, and the USA. The French company intends to raise **10 million euros** to support the entry of ExOlin<sup>®</sup>, its insulin delivery device, in clinical trials before its launch to market, as well as the development of the MailPan<sup>®</sup>, its bioartificial pancreas. Defymed will be drawing on the support of specialist health and Medtech funds to do this.

Defymed works with many partners as part of its open innovation policy. For the development of MailPan<sup>®</sup>, Defymed benefits from the financial support of JRDF, a worldwide foundation that finances therapies for Type 1 diabetes, and partners including Semma Therapeutics, which specializes in the development of cellular therapies for the treatment of diabetes.

[Click here to download a selection of images](#)

### About Defymed:

Defymed was formed as a Medtech company spin-off from the Centre Européen d'Étude du Diabète (European Center for Diabetes Studies) in March 2011, specialized in the design and development of innovative medical devices for delivering therapeutic treatments. Defymed focuses on applications for the treatment of Type 1 diabetes.

The first product designed was MailPan<sup>®</sup>, an implantable bioartificial pancreas created to reestablish normal insulin production in Type 1 diabetes patients. The MailPan<sup>®</sup> prototype first saw the light of day thanks to the financial support of the European Commission, the Grand Est region, and BPI France.

The second product developed by Defymed is ExOlin<sup>®</sup>, a medical device for delivering insulin.

The company has an exclusive technology that enables it to customize its medical devices to meet other therapeutic applications. Defymed's strength lies in its network of national and international partners.

For further information, please see <https://defymed.com/>

Additional information and visuals available on request from the press department:

### OXYGEN | Press contact

2 rue d'Ingwiller - 67000 Strasbourg, France

#### Elise Cordier

+33 (0)36-722-0325 - [elisec@oxygen-rp.com](mailto:elisec@oxygen-rp.com)

#### Jérémie Lotz

+33 (0)61-125-4805 - [jlotz@oxygen-rp.com](mailto:jlotz@oxygen-rp.com)

**DEFYMED**

8 avenue Dante  
67200 Strasbourg, France  
Tel. +33 (0)39-041-0446

[www.defymed.com](http://www.defymed.com)